Allogeneic stem cell transplantation (allo-SCT) is an effective and potentially curative treatment for some cases of multiple myeloma (MM). The curative efficacy of allo-SCT may be largely attributed to its immunological activity, the graft-versus-myeloma (GVM) effect. To evaluate the kinetics of residual myeloma cells, we analyzed the follow-up bone marrow samples of three MM patients by means of a real-time molecular assay. We identified a consistent correlation between onset of graft-versus-host disease and disease response. These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation.
multiple myeloma; allogeneic transplantation After allogeneic stem cell transplantation (allo-SCT), the majority of multiple myeloma (MM) patients attain a clinical complete remission (CCR), and roughly half of them are also in molecular remission (MR). 1, 2 Since the postulated curative efficacy of allo-SCT is related to the graft-versus-myeloma (GVM) effect, post transplant therapeutic interventions are mainly based on immunomodulation. It is, therefore, important to have reliable methods to quantitate residual disease, since it has been shown that, in general, immunotherapy is more effective in the setting of minimal disease. 3 We have recently developed a real-time polymerase-chain-reaction (PCR) assay to quantitate the rearranged immunoglobulin heavy-chain (IgH) genes in myeloma patients. 4 Here, we present the clinical significance of post-transplant quantitative molecular follow-up of three MM patients.
Patients and methods

Patients
Patient characteristics are summarized in Table 1 . In all cases, the conditioning regimen consisted of busulfan 14 mg/kg and melphalan 140 mg/m 2 . All patients received G-CSF mobilized peripheral blood stem cells and GVHD prophylaxis consisted of cyclosporin A and methotrexate. All patients obtained CCR, as defined by EBMT guidelines. 5 Minimal residual disease analysis by real-time PCR Bone marrow genomic DNA was extracted using a DNAZOL method (GIBCO BRL, Gaithersburg, MD, USA). VDJ amplification and sequencing were performed as previously described. 6 Taqman real-time PCR was performed with patient-specific primers and probes derived from CDR2 and CDR3 regions. Amplification and fluorescence detection were carried out with the ABI PRISM 7700 SDS analytical thermal cycler (PE Biosystems, Foster City, CA, USA). Patient-specific standard curves were prepared cloning the tumor VDJ sequence into the pCRII plasmid (TA cloning kit, Invitrogen Corp., San Diego, CA, USA). Two reference curves were obtained for each patient, preparing serial 10-fold dilutions of the reference plasmid in a TE solution alone and in a TE solution containing 100 ng/ml of polyclonal genomic DNA. An independent b-actin TaqMan quantitative assay was performed for each patient in order to normalize each sample for DNA content. Specificity and sensitivity of our Taqman system were superimposable upon those obtained with qualitative nested-PCR.
Results
Patient 1
He developed grade II acute GVHD (aGVHD) followed by extensive chronic GVHD (cGVHD). At 6 months after allo-SCT, the patient was in partial remission with mixed chimerism and 7 months later he entered stable CCR, as defined by standard criteria, 5 with full donor marrow chimerism, but tumor plasma cells were still detectable by PCR. At 13 months from allo-SCT, after the occurrence of extensive chronic GVHD, he maintained his CCR status and became persistently PCR-negative (Figure 1a) . At the last follow-up, 3 years after transplantation, the BM is still in CCR and PCR-negative.
Patient 2
He developed grade I aGVHD and no cGVHD was observed. The response to allo-SCT was CCR. At 32 months after transplant, he reconverted to mixed chimerism and relapsed. In the post transplant period, all BM samples were positive by quantitative PCR analysis. Real-time PCR showed first a period of stable disease, followed by a progressive increase in myeloma cell genomes preceeding overt clinical relapse (Figure 1b ).
Patient 3
He had no signs of aGVHD, and only limited skin cGVHD was observed. At 6 months after transplant, he achieved CCR. Real-time PCR was persistently positive, with low levels of myeloma genomes. He had a one-log increase at month 17. In that period, the patient was treated with steroids for a membranous glomerulonephritis. Following steroid tapering, with persistence of cGVHD, the tumor genomes decreased (Figure 1c ).
Discussion
In order to better define the behavior of neoplastic cells after allo-SCT, we used real-time PCR to monitor residual disease in three CCR patients. Real-time PCR showed a decrease in plasma cell genomes in the period following conditioning chemotherapy. This observation suggests that high-dose chemotherapy is able to reduce tumor burden, but cannot completely eradicate the myeloma clone, as already shown by the sporadic occurrence of molecular remission (MR) after tandem autografting. 7, 8 Patient 1 achieved CCR in the presence of GVHD and then obtained Graft-versus-myeloma assessed by real-time PCR persistent MR. The gradual decrease in residual plasma cells concomitant with the occurrence of chronic GVHD suggests the pivotal role of GVM effect. Patient 3 developed limited chronic GVHD, and achieved CCR, but he retained persistent molecular disease. It is noteworthy that this patient showed a one-log transient increase in clonal cells during a period of steroid treatment for membranous glomerulonephritis, followed by a persistent reduction in tumor cells after steroid tapering. In this case, the temporal relationship between steroid modulation and modifications of tumor genomes is intriguing and might indicate that an immunological control of the disease was ongoing. On the contrary, patient 2 seems paradigmatic for the lack of GVM effect. He achieved a short CCR with a two-log decrease of tumor burden 1 month after transplantation. Complete clearance of residual disease was not observed and persistent PCR positivity was noted. Progressive increase of myeloma genomes occurred until clinical relapse 32 months after allo-HSCT. The duration of CCR was similar to that obtained after autologous transplantation, confirming the role of chemotherapy in inducing the remission in this patient. 9 Although we cannot exclude the existence of subclinical GVHD, this observation strengthens the hypothesis that for the maintenance of long-term CCR, a persistent GVM effect may be critical. The existence of a GVM effect forms the rationale for the use of nonmyeloablative allo-HSCT programs, since these strategies mainly rely on the immunotherapeutic component of the transplant. 10 The possibility of using quantitative monitoring of minimal disease as a surrogate marker of the GVM effect can be helpful in optimizing immunotherapeutical intervention such as cyclosporin tapering or donor lymphocyte infusions. Moreover, immunotherapeutic maneuvers are more effective in the presence of minimal disease, 3 and early intervention can retain curative activity while minimizing the procedure-associated side effects.
In conclusion, in a small series of patients, our study shows concordance between tumor burden modifications and occurrence of GVHD. Moreover, quantitative PCR has demonstrated that persistent molecular disease varies dynamically over time, with modifications that might be relevant in the clinical setting. Therefore, a longitudinal quantitative approach is possible, and may be used to discriminate, among PCR-positive patients, those who are at risk of impending relapse. In addition, real-time PCR analysis can represent a reliable tool to tailor therapeutical interventions, in particular in the nonmyeloablative setting.
